Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo- controlled, crossover trial

Neurology

Volumn 47, Issue 6, 1996, Pages 1457-1462

  Bever Jr , C T ^a,c,d   Anderson, P A ^a   Leslie, J ^b   Panitch, H S ^a,c   Dhib Jalbut, S ^a,c   Khan, O A ^a,c   Milo, R ^a   Hebel, J R ^a   Conway, K L ^a   Katz, E ^a   Johnson, K P ^a  

^a SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UMH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; POTASSIUM CHANNEL BLOCKING AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; MUSCLE WEAKNESS; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEIZURE; TREATMENT OUTCOME;

EID: 10544237271     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.6.1457     Document Type: Article

References (30)

1. McFarlin DE, McFarland HF. Multiple sclerosis. N Engl J Med 1982;307:1183-1188, 1246-1251.
2. Matthews WB, Batchelor JR, Acheson ED, Weller RO. Symptoms and signs. In: Matthews WB, ed. McAlpine's multiple sclerosis. Edinburgh: Churchill Livingstone, 1985:96-145.
3. Matthews WB, Batchelor JR, Acheson ED, Weller RO. Treatment. In: Matthews WB, ed. McAlpine's multiple sclerosis. Edinburgh: Churchill Livingstone, 1985:233-278.
4. Watson C. Effect of lowering body temperature on the symptoms and signs of multiple sclerosis. N Engl J Med 1959;261: 1253-1259.
5. Davis FA, Becker FO, Michael JA, Sorensen E. Effect of intravenous sodium bicarbonate edetate (Na2EDTA) and hyperventilation on visual and oculomotor signs in multiple sclerosis. J Neurol Neurosurg Psychiatry 1970;33:723-732.
6. Prineas JW, Wright RG. Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978;38:409-418.
7. Waxman SG. Membranes, myelin and the pathophysiology of multiple sclerosis. N Engl J Med 1982;306:1529-1533.
8. Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibers. J Physiol (Lond) 1981;313:301-315.
9. Bever CT, Young D, Anderson PM, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994;44:1054-1059.
10. Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983;60:353-362.
11. Davis FA, Stefoski D, Schauf CL. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-192.
12. Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine in patients with multiple sclerosis. Ann Neurol 1987;27:71-75.
13. Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41:1344-1348.
14. vanDiemen HAM, Polman CH, vanDongen TMMM, et al. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci 1993;116:220-226.
15. vanDiemen HAM, Polman CH, vanDongen TMMM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized placebo-controlled, double-blind, crossover study. Ann Neurol 1992;32:123-130.
16. Polman CH, Bertelsmann FW, vanLoenen AC, Koetsier JC. 4-Aminopyridine in the treatment of patients with multiple sclerosis: long-term efficacy and safety. Arch Neurol 1994;51: 292-296.
17. Bever CT, Leslie J, Camenga D, Panitch HS, Johnson KP. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol 1990;27:421-427.
18. Carter JL, Stevens JC, Smith B, et al. A double-blind, placebo-controlled crossover trial of 3,4 diaminopyridine in the symptomatic treatment of multiple sclerosis [abstract]. Ann Neurol 1993;34:272.
19. Leslie J, Bever CT. Analysis of 3,4 diaminopyridine in human serum by solid phase extraction and high performance liquid chromatography with ultraviolet detection. J Chromatogr 1989;496:214-222.
20. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
21. Medical Research Council. Aids to the examination of the peripheral nervous system, vol 45. London: Her Majesty's Stationery Office, 1976:1.
22. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns and prediction. Neurology 1991;41:685-691.
23. Rao SM and the NMSS Cognitive Function Study Group. A manual for the brief repeatable battery of neuropsychology tests in multiple sclerosis. New York: National Multiple Sclerosis Society, 1990.
24. Rao SM, Leo GJ, Ellington L, Nauretz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991;41: 692-696.
25. Bever CT, Grattan L, Panitch HS, Johnson KP. The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary study. Multiple Sclerosis 1995;1:165-169.
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
27. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 1983;308:173-180.
28. Polman CH, Bertelsmann FW, deWaal R, et al. 4-Aminopyridine is superior to 3,4 diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994;51:1136-1139.
29. McEvoy DM, Windebank AJ, Daube JR, Low PA. 3,4 Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321:1567-1571.
30. Bever CT Jr, Young D, Tierney D, et al. The pharmacokinetics and tolerability of a slow-release formulation of 4-aminopyridine in multiple sclerosis patients [abstract]. Neurology 1995;45(suppl 4):A351.